HepG2 liver models for metabolism and toxicity screening
In drug development and toxicology, HepG2 cells are widely used as a human liver-derived model for metabolism, toxicity and lipid handling. Their ease of culture and compatibility with high-throughput formats make HepG2 a practical choice for early screening. With authenticated HepG2 stocks from Cytion, laboratories can run reproducible, scalable hepatic assays.
What are HepG2 cells?
Originating from a human hepatocellular carcinoma, HepG2 cells retain many liver-like functions:
Expression of key metabolic enzymes and transporters.
Capacity for albumin production and lipid metabolism.
Compatibility with both 2D and spheroid culture systems.
Cytion’s HepG2
stocks are carefully characterised to support these hepatic features.
Applications of HepG2 in drug discovery and safety
Because of their liver-related properties, HepG2 cells are widely applied in:
Hepatotoxicity screening, identifying compounds with potential liver liabilities.
Metabolism studies, exploring biotransformation and metabolite formation patterns.
Lipid metabolism and NAFLD research, modelling steatosis and related pathways.
Transporter studies for hepatic uptake and efflux processes.
These assays provide early insights into hepatic safety and pharmacokinetics before more complex models are used.
Strengths and limitations of HepG2
To make best use of HepG2, researchers must consider both advantages and constraints.
Strengths
Human origin relevant to clinical metabolism and toxicity.
Straightforward, robust culture suitable for automation and high-throughput screens.
Availability of protocols for 3D spheroids that enhance hepatic phenotype.
Limitations
Cancer origin means HepG2 does not fully replicate normal hepatocytes.
Enzyme expression patterns may differ from primary liver tissue.
Long-term culture and passage number can influence functional readouts.
Combining HepG2 data with primary hepatocyte or organoid models can strengthen overall safety assessment.
Practical tips for HepG2 culture and assay optimisation
To generate reliable data from HepG2 assays:
Standardise media formulations, especially when studying metabolism or lipid handling.
Control seeding density and culture duration, as these affect enzyme activity and sensitivity.
Consider 3D formats, such as spheroids, when more mature hepatic functions are needed.
Use appropriate controls, including known hepatotoxins and non-toxic comparators.
Starting with Cytion’s HepG2
stocks provides a stable basis for these optimisations.
How Cytion supports HepG2-based liver research
Cytion supports hepatic research teams and safety scientists working with HepG2 by:
Delivering authenticated, mycoplasma-free HepG2 cells.
Providing culture recommendations for both 2D and 3D formats.
Assisting with troubleshooting of growth or functional assay performance.
This technical support helps laboratories integrate HepG2 into coherent, multi-model liver research strategies.
Conclusion: HepG2 as a practical hepatic screening model
For early hepatotoxicity assessment, metabolism research and lipid studies, HepG2 offers a practical balance of relevance, robustness and throughput. By sourcing HepG2 from Cytion and managing culture conditions carefully, research groups can obtain consistent, informative data that feed into better-informed development and safety decisions.